Agios Pharmaceuticals, Inc.

NasdaqGS:AGIO Stock Report

Market Cap: US$2.0b

Agios Pharmaceuticals Valuation

Is AGIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AGIO ($35.42) is trading below our estimate of fair value ($370.26)

Significantly Below Fair Value: AGIO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGIO?

Key metric: As AGIO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AGIO. This is calculated by dividing AGIO's market cap by their current earnings.
What is AGIO's PE Ratio?
PE Ratio3x
EarningsUS$674.31m
Market CapUS$2.02b

Price to Earnings Ratio vs Peers

How does AGIO's PE Ratio compare to its peers?

The above table shows the PE ratio for AGIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.1x
PTGX Protagonist Therapeutics
14.5x-36.0%US$2.5b
MNKD MannKind
87.6x38.8%US$1.9b
CPRX Catalyst Pharmaceuticals
17.8x17.5%US$2.5b
ADMA ADMA Biologics
60.4x30.5%US$4.1b
AGIO Agios Pharmaceuticals
3x-57.3%US$2.0b

Price-To-Earnings vs Peers: AGIO is good value based on its Price-To-Earnings Ratio (3x) compared to the peer average (45.1x).

Price to Earnings Ratio vs Industry

How does AGIO's PE Ratio compare vs other companies in the US Biotechs Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.15.2x27.5%
AGIO Agios Pharmaceuticals
 3x-57.3%US$2.02b
ROIV Roivant Sciences
1.8x-58.7%US$8.42b
INBX Inhibrx Biosciences
0.1xn/aUS$211.35m
AGIO 3.0xIndustry Avg. 15.2xNo. of Companies12PE020406080100+
12 CompaniesEstimated GrowthMarket Cap
Industry Avg.15.2x27.5%
AGIO Agios Pharmaceuticals
 3x-57.3%US$2.02b
No more companies

Price-To-Earnings vs Industry: AGIO is good value based on its Price-To-Earnings Ratio (3x) compared to the US Biotechs industry average (15.2x).

Price to Earnings Ratio vs Fair Ratio

What is AGIO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGIO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3x
Fair PE Ratio7.2x

Price-To-Earnings vs Fair Ratio: AGIO is good value based on its Price-To-Earnings Ratio (3x) compared to the estimated Fair Price-To-Earnings Ratio (7.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AGIO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$35.42
US$57.29
+61.7%
14.2%US$75.00US$46.00n/a7
Dec ’25US$59.39
US$53.88
-9.3%
6.6%US$57.00US$46.00n/a8
Nov ’25US$44.87
US$53.88
+20.1%
6.6%US$57.00US$46.00n/a8
Oct ’25US$42.47
US$54.50
+28.3%
7.1%US$57.00US$46.00n/a6
Sep ’25US$45.91
US$54.33
+18.3%
8.1%US$60.00US$46.00n/a6
Aug ’25US$44.50
US$53.83
+21.0%
8.9%US$60.00US$46.00n/a6
Jul ’25US$43.38
US$52.83
+21.8%
8.9%US$61.00US$46.00n/a6
Jun ’25US$36.34
US$46.00
+26.6%
18.2%US$59.00US$33.00n/a5
May ’25US$33.66
US$40.67
+20.8%
20.3%US$49.00US$29.00n/a6
Apr ’25US$28.86
US$40.67
+40.9%
20.3%US$49.00US$29.00n/a6
Mar ’25US$32.27
US$40.67
+26.0%
20.3%US$49.00US$29.00n/a6
Feb ’25US$22.96
US$40.17
+74.9%
20.2%US$49.00US$28.00n/a6
Jan ’25US$22.27
US$38.33
+72.1%
19.0%US$49.00US$28.00n/a6
Dec ’24US$22.90
US$38.00
+65.9%
19.2%US$49.00US$28.00US$59.396
Nov ’24US$21.30
US$38.50
+80.8%
13.8%US$46.00US$32.00US$44.876
Oct ’24US$24.75
US$38.83
+56.9%
13.3%US$46.00US$32.00US$42.476
Sep ’24US$28.17
US$38.83
+37.9%
13.3%US$46.00US$32.00US$45.916
Aug ’24US$26.79
US$38.67
+44.3%
12.8%US$46.00US$32.00US$44.506
Jul ’24US$28.32
US$38.67
+36.5%
12.8%US$46.00US$32.00US$43.386
Jun ’24US$25.71
US$36.67
+42.6%
10.2%US$41.00US$32.00US$36.346
May ’24US$23.19
US$36.83
+58.8%
9.8%US$41.00US$32.00US$33.666
Apr ’24US$22.97
US$36.83
+60.4%
9.8%US$41.00US$32.00US$28.866
Mar ’24US$25.01
US$36.83
+47.3%
9.8%US$41.00US$32.00US$32.276
Feb ’24US$29.56
US$36.20
+22.5%
8.8%US$40.00US$32.00US$22.965
Jan ’24US$28.08
US$36.20
+28.9%
10.7%US$43.00US$32.00US$22.275
Dec ’23US$29.39
US$36.20
+23.2%
10.7%US$43.00US$32.00US$22.905

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agios Pharmaceuticals, Inc. is covered by 32 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
George FarmerBMO Capital Markets Equity Research
Alec StranahanBofA Global Research